The role of TP53 mutation in transformation of follicular lymphoma (FL) to diffuse large B-cell lymphoma (t-FL) was examined in a panel of 91 lymph node biopsies derived from 29 patients pre-and post-transformation. The entire TP53 coding sequence was screened and immunocytochemistry performed to determine expression of p53 and its key regulator MDM2. A total of 10 mutations were detected in eight patients (28%), although none were present at FL diagnosis. Mutations were not detected solely at the time of transformation; in three patients, mutated TP53 arose in at least one antecedent FL sample (6 months, 2.5 years and 4 years prior to transformation). Loss of heterozygosity at the TP53 locus occurred in 2/20 informative patients (only in t-FL samples). p53 staining was positive in 82% (9/11) of available biopsies with a missense mutation, and negative in 71% (45/63) with wtTP53. MDM2 expression was significantly higher in t-FL samples (mean 72% positive; 95% confidence interval (95% CI) 68-76%) than FL (mean 58% positive; 95% CI 54-62%) (Po0.001) but did not correlate with TP53 status. TP53 mutation has only a limited role in the transformation of FL, exerting a heterogeneous influence upon phenotypic change. In contrast, dysregulation of MDM2 is frequent and may provide a more rational therapeutic target.
Introduction
Follicular lymphoma (FL) accounts for approximately onequarter of the non-Hodgkin's lymphomas (NHL) in the west. 1 Although the median survival from diagnosis for all patients is of the order of 8-10 years, 2, 3 transformation to a more aggressive histological subtype, most typically diffuse large B-cell lymphoma (DLBCL), occurs frequently. [4] [5] [6] [7] [8] This event typically carries a poor prognosis, 2, 7 although durable remissions have been observed in a subset of individuals following high-dose therapy. 9, 10 Transformation provides an important model for the study of oncogenesis and a number of recurring secondary events are recognised that may be of mechanistic significance. These include acquisition of recurrent chromosomal aberrations including loss of 17p and gains at 12q, [11] [12] [13] [14] inactivation of CDKN2A and CDKN2B, 15 dysregulation of c-MYC 16, 17 and translocations, 18 gains 13 and mutations involving BCL-6.
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Despite each individual genomic insult being observed in only a subset of patients, the resulting clinical and histologic phenotypes are similar. The p53 protein, encoded by TP53 tumour suppressor gene (17p13), lies at the point of convergence of a number of cellular stress pathways. 22, 23 Activation induces cell cycle arrest, DNA repair and, in irreparably damaged cells, apoptosis. MDM2 is a key regulator of p53, exerting its effect by blocking the p53 transactivation domain and targeting the protein for proteasome degradation. Inactivation of MDM2 occurs by a number of pathways, and results in p53 activation. In a tightly controlled negative feedback loop, MDM2 transcription itself is targeted by p53. Mutations of TP53 are the most commonly observed in cancer; 24 in NHL, their frequency varies with histological subtype. 25 In FL, mutations are infrequent, while in de novo DLBCL they are more common and may correlate with an adverse prognosis. 26, 27 Both mutations in TP53 and overexpression of the p53 protein (a surrogate for mutated TP53) have been observed in a subset of histologically transformed FL (t-FL) samples. [28] [29] [30] Paired analysis of material pre-and post-transformation has demonstrated wildtype (wt) TP53 in the antecedent FL samples, with the emergence of a mutated subclone at the time of transformation. Additionally, mutated TP53 has been identified in a small number of untransformed FL cases mutations and is associated with either subsequent transformation or an aggressive clinical course. The temporal sequence of subclone emergence in the evolution of FL is unclear. Indeed despite a wealth of information on mutant TP53 in many malignancies, only a limited amount of data are available from studies that have sequentially analysed the same tumour. 22, 31 In order to better establish the frequency and determine the timing of TP53 mutation acquisition in FL that transforms to DLBCL, a panel of 91 sequentially collated lymph node biopsies derived during the clinical course of this disease were studied. The entire coding sequence (exons 2-11) of TP53, donoracceptor splice sites and the non-coding first exon were screened, in accordance with recent recommendations, 32 to accurately determine the incidence of mutations, and to examine loss of heterozygosity (LOH). Molecular analysis was correlated with immunohistochemical (IHC) assessment of p53 and MDM2 expression.
Materials and methods

Patient and specimens
A total of 91 tumour specimens derived from 29 patients (median age 52 years; range 27-73) with FL that subsequently transformed to DLBCL were identified from the tissue archive at St Bartholomew's Hospital, London (Figure 1) . Inclusion was based upon the availability of at least one sample of DLBCL and antecedent FL from each patient. If available, additional samples obtained at the time of progression either pre-or posttransformation were also examined. In the case of patient 14, DNA from the FL presentation sample failed to amplify; however, given the pattern of mutation in biopsies taken at recurrence, the patient has been reported in this series (no IHC analysis was performed on the initial biopsy). Histology was reviewed prior to inclusion, and classified according to the WHO system. 33 As a whole, transformation occurred at a median of 3.8 years (range 3 months-15 years) after presentation, and after a median of three (range 0-13) prior therapies. Median follow-up from diagnosis for all patients at the time of analysis was 6.7 years (range 2.0-19.1 years). Presentation lymph nodes were available from 13/29 patients. Genomic DNA was extracted from snap-frozen lymph nodes by conventional methods. Local Research Ethics Committee approval was obtained prior to study initiation.
TP53 mutation detection
The entire coding sequence of TP53 was examined by PCR, fluorescent single-strand conformation polymorphism (FSSCP) analysis and subsequent sequencing. PCR amplification was carried out using Amplitaq Gold polymerase (Applied Biosystems, Warrington, UK) in the buffer supplied by the manufacturer; 200 mM each dNTP; 0.5 pmol/ml each primer and 2 ng/ml genomic DNA (primers available on request). For FSSCP, primers were labelled with FAM or HEX and depending upon yield, fluorescent-labelled PCR products were diluted from 1:10 to 1:40 with water. In total, 1-2 ml of diluted product was mixed with 0.5 ml of ROX-500 size standards (Applied Biosystems) and 10.5 ml of HI-Deionised Formamide (Applied Biosystems). The samples were denatured at 951C for 2 min and snap cooled on ice. FSSCP analysis was carried out on a 3100 Genetic Analyser (Applied Biosystems) at 18 and 301C using 5% Genescan polymer containing 10% glycerol and 1 Â TAPS buffer with EDTA. Data was analysed using Genescan 3.7.1 and Genotyper 2.5 software (Applied Biosystems). Two independent observers visually examined each electropherogram trace.
Bidirectional sequencing was performed using BigDye Terminator chemistry (Applied Biosystems) and the PCR primers. Electrophoresis was performed on a 310 Genetic Analyser (Applied Biosystems) and data analysed using Sequence Analysis 3.0 (Applied Biosystems); SeqMan (DNAStar, Madison, WI, USA) and by visual inspection of electropherograms. Nucleotide number was assigned according to sequence U94788. LOH was examined at five common polymorphic sites: 11827 G4C, 11992 C4A, 11951_11952ins16, 12139 G4C and 17708 A4T. The PowerPlex16 multiplex PCR singletandem repeat (STR) genotyping system (Promega, Southampton, UK) was performed according to the manufacturer's instructions. IGH/BCL2 atypical PCR followed the methodology of Buchonnet et al.
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Immunohistochemistry
Original paraffin blocks representing 77/91 of the samples analysed for TP53 mutation were located for IHC analysis (in 20 patients, both the FL and DLBCL samples were available). Paraffin-embedded 4 mm sections were cut onto TESPA-coated slides, then dewaxed and blocked in hydrogen peroxide/ methanol solution. Antigen retrieval for p53 was performed overnight at 601C with antigen unmasking solution (H-3300, Vector Laboratories, Peterborough, UK), and for MDM2 using the pressure-cooking technique. 35 Primary antibodies were diluted and incubated as follows: p53 (DO7; Dako, Glostrup, Denmark) 1:100 for 40 min and MDM2 (1B10; Novocastra, Newcastle, UK) 1:100 overnight. Sections were then stained using the Vector Elite ABC kit (PK6100, Vector Laboratories, Peterborough, UK) and chromogen diaminobenzidine (Biostat, Stockport, UK). Each case and antibody had an individual negative control. p53 was scored by determining the percentage of cells positive for p53. In the FL cases, the entire node was scanned at low power and the number of positive cells within 10 follicles scored at Â 40 magnification. For t-FL, the entire section was initially scanned at low power and the number of positive cells scored in 10 fields at Â 40 magnification. Only nuclear staining was considered positive for MDM2, with the percentage of positive cells scored as for p53. Consensus scoring was performed independently by two of three Histopathologists (AL, AN or MC).
Statistical analysis
Survival analysis data were censored according to the methods of Kaplan and Meier. 36 Differences between subgroup survival was compared using the log-rank test, and for IHC expression between groups the nonparametric Mann-Whitney U test was used. Significance was set at Po0.05.
Results
Mutation analysis of TP53 in sequential samples
Examination of the entire coding sequence and the first noncoding exon of TP53 revealed no mutations in any of the 13 biopsies obtained at the time of FL diagnosis. At recurrence, 10 mutations were identified in 8/29 (28%) patients ( Figure 1 and Table 1 ). These were present in 8/54 (15%) FL samples (4/29 patients, 14%) and 9/37 (24%) t-FL samples (7/29 patients, 24%). Mutations were in the main missense (5/10), with the remainder accounted for by two nonsense mutations, a splice site mutation, a branch site mutation and a single base insertion ( Figure 2 ). All were confined to exons 5-7 and their adjacent exon-intron boundaries. Eight of these mutations have previously been reported.
In three patients mutated TP53 was documented in at least one FL sample prior to transformation. The interval between documentation of mutation and histological transformation was 6 months, 2.5 years and 4 years in patients 21, 3 and 9, respectively. Mutations were identified first at the time of transformation in three patients (patients 4, 22 and 24) with wtTP53 present in all antecedent FL biopsies. One patient acquired a mutation at late FL recurrence (grade 3a FL), 7 years after entering complete remission from t-FL (patient 29). In one patient for whom no suitable pretransformation biopsy was available (failed extraction), mutated TP53 was documented in the t-FL sample but not at subsequent FL recurrence (patient 14).
Recurrent disease after initial successful treatment of t-FL was biopsied in 6/8 patients with mutations. The identical mutation was observed in four patients; the histology at recurrence was FL in two patients (9 and 21) and DLBCL in two patients (4 and 24).
In one patient (patient 14), the mutated subclone was eradicated by therapy; wtTP53 was documented at the time of recurrence with follicular histology and for patient 29 the clinical history is documented above.
Two distinct mutations were observed in two of the patients. Tumour material from patient 3 documented identical simultaneous mutations both in FL and t-FL samples (14031 A4G (N235S) and IVS6-36 (G4C)). Although the latter mutation has not been previously reported, a germline variant at IVS6-39 is associated with stabilisation of p53 protein and a cancer phenotype. 37 Two and one-half years elapsed between documentation of mutation and transformation. Distinct mutations in the FL and t-FL phases of the illness were documented in patient 21. A grade 1 FL biopsy, taken 6 years from diagnosis, demonstrated the 13397 C4T (R213X) nonsense mutation in exon 6. Response to therapy was unsatisfactory and subsequent biopsy demonstrated histological transformation with a nonsense mutation 13085 C4T (Q136X) in exon 5. At recurrence 1 year following successful therapy, the R213X was again documented in a grade 1 FL sample in the absence of the Q136X mutation. The patient remains alive and in remission 12 years post therapy. The pattern of TP53 common polymorphism and multiplex STR analysis confirmed patient identity in the three samples. PCR across the IGH/BCL2 breakpoint in each sample produced a 1.7 kb product. Sequencing of cloned product confirmed an identical breakpoint at an atypical site 3 0 of BCL2, thus indicating divergence of two subclones, with distinct mutations, from a common precursor (Figure 3) .
Overall survival from diagnosis or documented histological transformation was not significantly different between those patients with a TP53 mutation and those with wtTP53 (P ¼ 0.19 and P ¼ 0.45, respectively). Eight neutral polymorphic variants were identified, and served as verification of patient-specific sample identity. Using the five most common polymorphic sites, allelic status was used to identify LOH in 2/20 informative patients. LOH was only present in transformed samples and in the presence of mutated TP53. In both cases, the mutation had also been initially documented in the same sample. Survival in these two patients (4 and 22) was short at 17 and 1 months, respectively, from documentation of LOH. Representative SSCP and direct sequencing trace of TP53 mutation (patient 22). The homozygous mutation 13129_13130insC in DLBCL is demonstrated (lower panel) compared to wtTP53 in the FL sample.
Sequential TP53 mutation in FL transformation AJ Davies et al 
IHC analysis of p53 and MDM2 expression
A total of 77 paraffin blocks were available for immunohistochemistry (14 with mutated TP53; 63 wtTP53). Greater than 10% nuclear positivity was selected to represent p53 overexpression. 27 Overexpression was observed in only 9/14 (64%) of the available samples with TP53 mutations (Table 1) . Concordance with missense mutations was 9/11 (82%). p53 expression was not detected in the presence of either the splice site or insertion mutations. In samples with wtTP53, staining was negative in 45 of 63 samples (71%), and positive in 18 samples (29%). MDM2 expression was predominantly centroblastic (Figure 4 ) and higher in t-FL samples (mean 72%; 95% CI 68-76%) compared to untransformed FL (mean 58%; 95% CI: 54-62%) (Po0.001) (Figure 5a ). Paired analysis of samples where both pre and posttransformation blocks were available (n ¼ 20) demonstrated that despite the overlap in percentage staining between FL and t-FL in the 17/20 cases, transformation was accompanied by an increase in MDM2 expression of between 10 and 45% (Figure 5b) . Furthermore, differential regions of positivity could be observed in t-FL that had residual areas of FL. This difference remained significant in subgroup analysis of patients that both retained wtTP53 (FL mean 62% (95% CI: 58-67%), t-FL mean 74% (95% CI: 67-81%), Po0.005) and those that acquired a mutation at any time during the disease course (FL mean 49% (95% CI:43-56%), t-FL mean 74% (95% CI:67-77%), Po0.005). There was no difference in MDM2 expression between samples with wt (mean 67% (95% CI: 63-70%)) and mutated TP53 (mean 62%;95% CI: 55-69%) (P ¼ 0.256).
Discussion
In this large analysis of sequentially collated samples from patients with FL that undergo histological transformation, we have determined that oncogenic pathways involving mutation of TP53 contribute to histological transformation in only the minority of individuals. The observed temporal heterogeneity and the variable influence of mutation upon histologic phenotype demonstrate in vivo the differing functional consequence of aberrant p53. Such molecular heterogeneity has been a predominant feature in attempts to identify unifying mechanisms of FL transformation. 17, 38, 39 Two previous studies have screened smaller patient cohorts and employed more limited genomic analysis to assess the contribution of TP53 mutation to transformation. 28, 29 The observed frequencies differed significantly at 26 28 and 80% 29 in the t-FL sample. In this study, TP53 mutations were identified in only 28% of patients despite screening 91 biopsies from 29 patients and the entire coding sequence of the gene. In t-FL, the frequency was in broad agreement with that reported in de novo DLBCL. 26, 27 Although no mutations were detected in the presentation FL biopsies, TP53 mutations were present in 14% of FL samples. The study was designed only to examine TP53 status in cases that ultimately transformed, yet the mutation frequency is higher than for unselected FL series. 25, 40 This over-representation in our population suggests that mutation occurrence, despite variable latency, presages the transforming event.
The longitudinal nature of this study demonstrates the functional nonequivalence of mutations accumulated during the clinical course of FL. Detection of a mutated subclone in the FL phase of the illness did not predicate a rapidly accelerated death, indicating that at least some mutations are of low penetrance, and consistent with the observation that some mutated p53 proteins have wt activity. 41 The R213X mutation observed in patient 21 has previously been documented as a low penetrance germline mutation in a child with an adrenocortical tumour, but without a Li-Fraumeni phenotype or significant family history of cancer. 42 In such patients, there is an obligate requirement for additional 'hits' in order for transformation to proceed. In other patients, mutations were identified only at the time of histological transformation supporting a more critical mechanistic role.
TP53 mutation detection strategies that examine both the whole coding sequence and donor-acceptor splice sites have infrequently been reported in NHL; [43] [44] [45] [46] to our knowledge, this is the first report in FL. Although in this series all mutations were identified by primer pairs covering exons 5-7 inclusive, incomplete genomic screens (typically limited to exons 5-9) are a well-recognised source of detection bias. 32 Using IHC as a surrogate marker is similarly flawed, yet precise characterisation of mutation status is essential if p53-MDM2 directed therapies are to be appropriately targeted in their translation from the laboratory to the clinic. 47 By examination of informative polymorphic markers, we were able to demonstrate infrequent LOH at the TP53 locus. This occurred only upon transformation and was associated with an adverse outcome. Karyotypic analysis has suggested that loss of 17p occurs frequently (19%), although late, in the cytogenetic evolution of FL 14 and has been associated with higher histological grade. 48 Our observations are, however, more consistent with conventional and array-based comparative genomic hybridisation (CGH) studies of sequential FL/t-FL pairs that demonstrate only infrequent loss of 17p upon transformation. 11, 13 Thus, the minority of transformation events were associated with the TP53 mutation or LOH. The alternative oncogenic mechanisms that result in phenotypic change as yet remain unclear; their elucidation hampered by limited sample availability for paired analysis. Gene expression profiling has implicated dysregulation of c-MYC and some of its target genes in a subset of patients. 17 In the Em-MYC mouse model of lymphomagenesis, an accelerated aggressive tumour phenotype is demonstrated in the presence of TP53 loss. 49 Inactivation of apoptosis by overexpression of BCL2 also results in a similarly aggressive course irrespective of TP53 status. 50 Extrapolating to FL, overexpression of BCL2 and dysregulation of c-MYC in a subset of patients upon transformation may account for the retention of the wt gene in over two-thirds of cases by relieving the selective pressure on TP53 to mutate.
MDM2 expression was high in transformed DLBCL and was independent of TP53 status. Increased expression in sequential samples pre-and post-transformation demonstrated that despite some overlap between histological groups, this change is of biological significance. Increased expression occurred both in the presence of TP53 mutation/deletion and in cases where wtTP53 was retained, suggesting that it occurred by a p53-independent mechanism. Such overexpression has been previously documented in B-cell lymphoma 51, 52 and has been reported in a small number of transformed cases. 53 In the Em-MYC model, haploinsufficency of the MDM2 allele results in a marked inhibitory effect on lymphoma development. Located at 12q14, human MDM2 is amplified in soft-tissue sarcoma with resulting protein overexpression; 54 however in NHL, MDM2 expression is increased in the absence of any genomic copy number gain. 46, 51, 52 However, in t-FL disomy may not be the case, with CGH analysis demonstrating gains at 12q12-14 in 50% of t-FL samples.
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Although this study confirms TP53 mutation as a contributory genetic mechanism in the process of transformation, the variable functional consequences and limited frequency suggests that targeting p53 may have only limited clinical application, instead targeting MDM2 overexpression on transformation may hold the greater promise.
